{
    "Trade/Device Name(s)": [
        "ARK EDDP Assay",
        "ARK\u2122 EDDP Assay"
    ],
    "Submitter Information": "ARK Diagnostics, Inc.",
    "510(k) Number": "K182779",
    "Predicate Device Reference 510(k) Number(s)": [
        "K151395"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJR"
    ],
    "Summary Letter Date": "September 28, 2018",
    "Summary Letter Received Date": "October 1, 2018",
    "Submission Date": "November 19, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.3620"
    ],
    "Regulation Name(s)": [
        "Methadone test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "EDDP"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Beckman Coulter AU680 automated clinical chemistry analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay",
        "Absorbance measurement (spectrophotometric)"
    ],
    "Methodologies": [
        "Enzyme immunoassay (EIA)"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for ARK EDDP Assay, a homogeneous enzyme immunoassay for qualitative and semiquantitative determination of EDDP in human urine using automated clinical chemistry analyzers",
    "Indications for Use Summary": "Immunoassay for qualitative and/or semiquantitative determination of EDDP in human urine at cutoff concentrations of 100 ng/mL and 300 ng/mL, intended for laboratory use with automated clinical chemistry analyzers; preliminary test result requires confirmatory testing by GC/MS or LC-MS/MS",
    "fda_folder": "Toxicology"
}